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Materials and Methods 
 
Unless otherwise stated, reactions were performed in flame-dried glassware under an argon 
or nitrogen atmosphere using dry, deoxygenated solvents. Solvents were dried by passage 
through an activated alumina column under argon. Commercially obtained reagents were 
used as received. Chemicals were purchased from Sigma Aldrich/Strem/Alfa 
Aesar/Oakwood Chemicals and used as received.  Reaction temperatures were controlled 
by an IKAmag temperature modulator. Glove box manipulations were performed under a 
nitrogen atmosphere. Thin-layer chromatography (TLC) and preparatory TLC was 
performed using E. Merck silica gel 60 F254 precoated plates (0.25 mm) and visualized by 
UV fluorescence quenching, KMnO4, or p-anisaldehyde staining. SiliaFlash P60 
Academic Silica gel (particle size 0.040–0.063 mm) was used for flash chromatography. 
Analytical chiral HPLC was performed with an Agilent 1100 Series HPLC utilizing a 
Chiralpak IC column (4.6 mm x 25 cm) or Chiralpak AD-H column (4.6 mm x 25 cm), 
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both obtained from Daicel Chemical Industries, Ltd. with visualization at 210 nm. 
Analytical SFC was performed with a Mettler SFC supercritical CO2 analytical 
chromatography system utilizing a Chiralpak OJ-H column (4.6 mm x 25 cm) obtained 
from Daicel Chemical Industries, Ltd. with visualization at 210 nm. 1H NMR spectra were 
recorded on a Bruker Avance HD 400 MHz spectrometer and are reported relative to 
residual CHCl3  (δ 7.26 ppm). 13C NMR spectra were recorded on a Bruker Avance HD 
400 MHz spectrometer and are reported relative to residual CDCl3  (δ 77.16 ppm). Data for 
1H NMR are reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, 
sept = septuplet, m = multiplet, br s = broad singlet. Data for 13C NMR are reported in 
terms of chemical shifts (δ ppm). Some reported spectra include minor solvent impurities 
of benzene (δ 7.36 ppm), water (δ 1.56 ppm), ethyl acetate (δ 4.12, 2.05, 1.26 ppm), 
methylene chloride (δ 5.30 ppm), grease (δ 1.26, 0.86 ppm), and/or silicon grease (δ 0.07 
ppm), which do not impact product assignments. IR spectra were obtained using a Perkin 
Elmer Paragon 1000 spectrometer using thin films deposited on NaCl plates and reported 
in frequency of absorption (cm-1). High resolution mass spectra (HRMS) were obtained 
from the Caltech Mass Spectral Facility using a JEOL JMS-600H High Resolution Mass 
Spectrometer in fast atom bombardment (FAB+) or electron ionization (EI+) mode, or an 
Agilent 6200 Series TOF with an Agilent G1978A Multimode source in electrospray 
ionization (ESI+), atmospheric pressure chemical ionization (APCI+), or mixed ionization 
mode (MM: ESI-APCI+). Optical rotations were measured with a Jasco P-2000 
polarimeter operating on the sodium D-line (589 nm), using a 100 mm pathlength cell and 
are reported as: [α]DT (concentration in g/100 mL, solvent).  
 
List of Abbreviations: ee – enantiomeric excess, HPLC – high-performance liquid 
chromatography, SFC – supercritical fluid chromatography, TLC – thin-layer 
chromatography, EtOAc – ethyl acetate, THF – tetrahydrofuran, IPA – isopropanol, DMF 
– dimethylformamide 
 
Preparation of Known Compounds: Previously reported methods were used to prepare 
ligand (S,)-L11 and 6-(bromomethyl)-4H-1,3-dioxin2. 
 
 
Experimental Procedures and Spectroscopic Data for the Synthesis of Allylic 
Alkylation Substrates 
 
 
 
Allyl 1-((4H-1,3-dioxin-6-yl)methyl)-2-oxocyclohexane-1-carboxylate (1a). Allyl 2-
oxocyclohexane-1-carboxylate3 (0.20 g, 1.1 mmol, 1 equiv), K2CO3 (0.76 g, 5.5 mmol, 5 
equiv), and  6-(bromomethyl)-4H-1,3-dioxin2 (0.30 g, 1.7 mmol, 1.5 equiv) were dissolved 
in acetone (5 mL). The resulting reaction mixture was heated under reflux for 18 h, 
whereupon the reaction was cooled to ambient temperature, filtered through celite with 
O
O
O
O
O
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acetone (10 mL), and concentrated under reduced pressure. The crude product was purified 
by silica gel flash column chromatography (15% EtOAc/hexanes) to give ester 1a as a 
colorless oil (0.26 g, 84% yield): 1H NMR (400 MHz, CDCl3) δ 5.83 (ddt, J = 17.2, 10.4, 
5.9 Hz, 1H), 5.31 – 5.12 (m, 2H), 4.89 – 4.80 (m, 2H), 4.66 (t, J = 2.6 Hz, 1H), 4.57 – 4.48 
(m, 2H), 4.14 – 4.09 (m, 2H), 2.76 (dt, J = 15.0, 1.6 Hz, 1H), 2.56 (dt, J = 13.9, 3.2 Hz, 
1H), 2.43 – 2.25 (m, 2H), 2.24 – 2.16 (m, 1H), 2.01 – 1.89 (m, 1H), 1.82 – 1.63 (m, 2H), 
1.56 (dddd, J = 17.0, 12.4, 8.4, 4.4 Hz, 1H), 1.36 (ddd, J = 13.9, 12.2, 4.7 Hz, 1H); 13C 
NMR (101 MHz, CDCl3) δ 206.4, 170.4, 150.3, 131.6, 118.8, 100.8, 90.3, 65.9, 63.7, 59.8, 
40.9, 38.8, 35.7, 27.5, 22.3; IR (Neat Film, NaCl) 3083, 2944, 2867, 2796, 1715, 1682. 
1648, 1451, 1372, 1314, 1175, 1092, 990, 927, 847, 761 cm-1; HRMS (FAB+) m/z calc’d 
for C15H19O5 [M+H]–H2: 279.1232, found 279.1224. 
 
 
 
 
Allyl 2-((4H-1,3-dioxin-6-yl)methyl)-1-oxo-1,2,3,4-tetrahydronaphthalene-2-
carboxylate (1b). Allyl 1-oxo-1,2,3,4-tetrahydronaphthalene-2-carboxylate3 (0.60 g, 2.8 
mmol, 1 equiv), Cs2CO3 (1.6 g, 5.0 mmol, 1.8 equiv), and  6-(bromomethyl)-4H-1,3-
dioxin2 (0.55 g, 3.1 mmol, 1.1 equiv) were dissolved in DMF (19 mL). The resulting 
reaction mixture was heated to 70 °C for 18 h, whereupon the reaction was cooled to 
ambient temperature, poured into H2O (40 mL), and the aqueous layer was extracted with 
EtOAc (3 x 25 mL). The combined organics were washed with brine (25 mL), dried over 
Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica 
gel flash column chromatography (10% EtOAc/hexanes) to give ester 1b as a pale yellow 
oil (0.65 g, 71% yield): 1H NMR (400 MHz, CDCl3) δ 8.04 (dd, J = 7.9, 1.4 Hz, 1H), 7.47 
(td, J = 7.5, 1.5 Hz, 1H), 7.34 – 7.27 (m, 1H), 7.21 (dd, J = 7.6, 1.2 Hz, 1H), 5.80 (ddt, J = 
17.2, 10.5, 5.5 Hz, 1H), 5.27 – 5.06 (m, 2H), 4.93 (s, 2H), 4.83 (t, J = 2.6 Hz, 1H), 4.56 
(dq, J = 5.6, 1.6 Hz, 2H), 4.20 (dt, J = 2.6, 1.3 Hz, 2H), 3.22 – 3.07 (m, 1H), 3.01 – 2.73 
(m, 3H), 2.64 (dt, J = 13.9, 4.6 Hz, 1H), 2.23 – 2.11 (m, 1H); 13C NMR (101 MHz, CDCl3) 
δ 194.2, 170.8, 150.5, 143.3, 133.6, 132.0, 131.6, 128.9, 128.3, 126.8, 118.3, 101.4, 90.5, 
66.0, 64.0, 56.8, 38.4, 30.5, 26.1; IR (Neat Film, NaCl) 2929, 2852, 1730, 1688, 1600, 
1453, 1371, 1313, 1294, 1232, 1172, 1093, 987, 950, 846, 744 cm-1; HRMS (FAB+) m/z 
calc’d for C19H19O5 [M+H]–H2: 327.1232, found 3267.1223. 
 
 
 
 
Allyl 3-((4H-1,3-dioxin-6-yl)methyl)-1-benzoyl-2-oxopiperidine-3-carboxylate (1c). 
Allyl 1-benzoyl-2-oxopiperidine-3-carboxylate4 (0.20 g, 0.70 mmol, 1 equiv), Cs2CO3 
O
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(0.41 g, 1.3 mmol, 1.8 equiv), and  6-(bromomethyl)-4H-1,3-dioxin2 (0.14 g, 0.77 mmol, 
1.1 equiv) were dissolved in DMF (5 mL). The resulting reaction mixture was heated to 70 
°C for 18 h, whereupon the reaction was cooled to ambient temperature, poured into H2O 
(40 mL), and the aqueous layer was extracted with EtOAc (3 x 10 mL). The combined 
organics were washed with brine (10 mL), dried over Na2SO4, and concentrated under 
reduced pressure. The crude product was purified by silica gel flash column 
chromatography (25% EtOAc/hexanes) to give ester 1c as a pale yellow oil (0.13 g, 49% 
yield): 1H NMR (400 MHz, CDCl3) δ 7.73 – 7.66 (m, 2H), 7.53 – 7.42 (m, 1H), 7.42 – 7.33 
(m, 2H), 5.99 (ddt, J = 17.2, 10.4, 6.0 Hz, 1H), 5.49 – 5.28 (m, 2H), 5.05 – 4.93 (m, 2H), 
4.78 (dt, J = 3.0, 1.5 Hz, 1H), 4.72 (ddt, J = 6.0, 1.7, 0.8 Hz, 2H), 4.20 (dq, J = 2.7, 1.2 Hz, 
2H), 3.94 – 3.66 (m, 2H), 2.98 – 2.87 (m, 1H), 2.74 – 2.62 (m, 1H), 2.50 – 2.33 (m, 1H), 
2.14 – 1.92 (m, 3H); 13C NMR (101 MHz, CDCl3) δ 175.1, 171.4, 171.3, 150.0, 135.9, 
131.9, 131.5, 128.3, 128.1, 119.8, 101.7, 90.7, 66.9, 64.0, 55.3, 46.5, 39.3, 30.3, 20.6; IR 
(Neat Film, NaCl) 2934, 2856, 1732, 1678, 1448, 1371, 1272, 1231, 1170, 1145, 1090, 
985, 939, 845, 721, 694, 647 cm-1; HRMS (FAB+) m/z calc’d for C21H24O6N [M+H]+: 
386.1604, found 386.1619. 
 
 
General Procedure for the Asymmetric Palladium-Catalyzed Allylic Alkylation 
 
 
 
(S)-2-((4H-1,3-Dioxin-6-yl)methyl)-2-allylcyclohexan-1-one (2a). In a nitrogen-filled 
glove box, to a 1 dram vial equipped with a stir bar was added Pd2(pmdba)3 (11 mg, 0.01 
mmol, 5 mol %), ligand (S)-L1 (13 mg, 0.025 mmol, 12.5 mol %), and THF (2 mL). The 
resulting mixture was stirred at 25 °C for 30 min, whereupon substrate 1a (56 mg, 0.20 
mmol, 1 equiv) was added. The vial was sealed, removed from the glove box, and stirred 
at 25 °C. After 18 h, the reaction mixture was concentrated under reduced pressure and the 
crude product was purified by preparatory TLC (10% EtOAc/hexanes) to give allyl 2a as 
a colorless oil (43 mg, 91% yield): 83% ee; [α]D25 –13.1 (c 1.9, CHCl3); 1H NMR (400 
MHz, CDCl3) δ 5.66 (ddt, J = 16.5, 10.6, 7.3 Hz, 1H), 5.09 – 4.99 (m, 2H), 4.95 (d, J = 5.4 
Hz, 1H), 4.88 (d, J = 5.4 Hz, 1H), 4.68 (t, J = 2.6 Hz, 1H), 4.26 – 4.11 (m, 2H), 2.58 – 2.45 
(m, 2H), 2.39 – 2.28 (m, 3H), 2.18 (d, J = 14.5 Hz, 1H), 1.84 (tdd, J = 6.7, 3.4, 1.6 Hz, 
1H), 1.79 – 1.69 (m, 5H); 13C NMR (101 MHz, CDCl3) δ 213.9, 151.5, 134.0, 118.4, 100.7, 
90.4, 63.9, 51.0, 39.5, 39.4, 39.0, 36.8, 27.3, 21.0; IR (Neat Film, NaCl) 3391, 3074, 2924, 
2854, 2795, 1705, 1681, 1638, 1445, 1372, 1311, 1196, 1172, 1124, 1093, 1021, 990, 911, 
847, 755, 640 cm-1; HRMS (FAB+) m/z calc’d for C14H19O3 [M+H]–H2: 235.1334, found 
235.1341; HPLC conditions: 3% IPA, 1.0 mL/min, Chiralpak AD–H column, λ = 210 nm, 
tR (min): major = 7.066, minor = 7.722. 
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Spectroscopic Data for the Asymmetric Palladium-Catalyzed Allylic Alkylation 
Products  
 
Please note that the absolute configurations of 2a–c were determined by analogy. 4,5 For 
respective HPLC conditions, please refer to Table S1. 
 
 
 
(S)-2-((4H-1,3-Dioxin-6-yl)methyl)-2-allyl-3,4-dihydronaphthalen-1(2H)-one (2b). 
Product 2b was prepared according to the general procedure to give a colorless oil (52 mg, 
91% yield): 82% ee; [α]D25 +0.254 (c 2.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 8.05 (dd, 
J = 7.8, 1.4 Hz, 1H), 7.47 (td, J = 7.5, 1.5 Hz, 1H), 7.35 – 7.29 (m, 1H), 7.27 – 7.19 (m, 
1H), 5.79 (dddd, J = 17.0, 10.3, 7.8, 7.0 Hz, 1H), 5.17 – 5.00 (m, 2H), 5.00 – 4.88 (m, 2H), 
4.74 (t, J = 2.6 Hz, 1H), 4.21 (dt, J = 2.5, 1.2 Hz, 2H), 3.02 (dd, J = 7.2, 5.5 Hz, 2H), 2.69 
(dq, J = 14.3, 1.3 Hz, 1H), 2.55 (ddt, J = 14.1, 7.0, 1.3 Hz, 1H), 2.34 – 2.27 (m, 1H), 2.27 
– 2.21 (m, 1H), 2.11 (ddt, J = 6.0, 4.8, 3.2 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 200.5, 
151.5, 143.2, 133.9, 133.2, 132.0, 128.8, 128.2, 126.7, 118.7, 100.8, 90.4, 64.0, 47.8, 39.6, 
38.8, 30.4, 25.3; IR (Neat Film, NaCl) 3072, 3004, 2929, 2859, 2794, 1677, 1600, 1454, 
1432, 1371, 1289, 1225, 1193, 1172, 1093, 1023, 989, 918, 847, 742 cm-1; HRMS (FAB+) 
m/z calc’d for C18H19O3 [M+H]–H2: 283.1334, found 283.1338; HPLC conditions: 4% 
IPA, 1.0 mL/min, Chiralpak IC column, λ = 210 nm, tR (min): major = 29.702, minor = 
23.387. 
 
 
 
 
(S)-3-((4H-1,3-Dioxin-6-yl)methyl)-3-allyl-1-benzoylpiperidin-2-one (2c). Product 2c 
was prepared according to the general procedure (toluene used in place of THF, reaction 
mixture heated to 40 °C) to give a pale yellow oil (66 mg, 95% yield): 99% ee; [α]D25 +11.4 
(c 3.3, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.61 – 7.31 (m, 5H), 5.76 (dddd, J = 17.1, 
10.3, 7.7, 6.9 Hz, 1H), 5.21 – 5.09 (m, 2H), 5.06 – 4.98 (m, 2H), 4.74 (td, J = 2.7, 0.8 Hz, 
1H), 4.23 (ddd, J = 2.6, 1.7, 0.8 Hz, 2H), 3.91 – 3.67 (m, 2H), 2.76 (dtd, J = 14.3, 1.7, 0.9 
Hz, 1H), 2.59 (ddt, J = 13.8, 6.9, 1.3 Hz, 1H), 2.31 (ddt, J = 13.8, 7.7, 1.1 Hz, 1H), 2.15 – 
2.09 (m, 1H), 2.04 – 1.95 (m, 3H), 1.93 – 1.83 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 
177.1, 175.6, 151.2, 136.7, 133.3, 131.5, 128.2, 127.8, 119.6, 101.2, 90.6, 64.1, 47.0 (2C), 
43.5, 41.7, 30.0, 20.0; IR (Neat Film, NaCl) 3346, 3072, 2945, 2868, 2795, 1678, 1600, 
1477, 1449, 1386, 1372, 1286, 1150, 1172, 1092, 1023, 990, 919, 846, 792, 725, 696 cm-
1; HRMS (FAB+) m/z calc’d for C20H24NO4 [M+H]+: 342.1705, found 342.1714; SFC 
O
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conditions: 5% IPA, 2.5 mL/min, Chiralpak OJ-H column, λ = 210 nm, tR (min): major = 
11.165, minor = 10.427. 
 
 
Determination of Enantiomeric Excess 
 
Please note racemic products were synthesized using Pd(PPh3)4 in place of Pd2(pmdba)3 
and (S)-L1. 
 
Table S1: Determination of Enantiomeric Excess 
 
 
 
 
General Procedure for Spirocyclic Formation 
 
 
 
(S)-Spiro[5.5]undec-9-ene-1,8-dione (3a). To a sealed Biotage microwave vial, allyl 2a 
(24 mg, 0.10 mmol, 1 equiv) and toluene (0.7 mL) were added. The reaction mixture was 
heated to 180 °C for 1 h, whereupon the reaction was cooled to 60 °C and a solution of 
Hoveyda-Grubbs 2nd generation catalyst (6.3 mg, 0.010 mmol, 0.10 equiv) in toluene (0.3 
mL) was added. The reaction mixture was then stirred an additional 18 h at 60 °C, cooled 
to ambient temperature, and directly purified by preparatory TLC (15% EtOAc/hexanes) 
Entry Product AssayConditions
Retention time
of major
isomer (min)
Retention time
of minor
isomer (min)
%ee
1
3
2
HPLC
Chiralpak IC
4% IPA
isocratic, 1 mL/min
SFC
Chiralpak OJ-H
5% IPA
isocratic, 2.5 mL/min
HPLC
Chiralpak AD-H
3% IPA
isocratic, 1 mL/min
O
O
O
O
O
O
BzN
O
O
O
29.702 23.387
11.165 10.427 99
82
7.066 7.722 83
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to give spirocycle 3a as a colorless oil (17 mg, 93% yield): [α]D25 –1.4 (c 1.1, CHCl3); 1H 
NMR (400 MHz, CDCl3) δ 6.81 (dt, J = 10.1, 4.1 Hz, 1H), 5.99 (dt, J = 10.0, 2.1 Hz, 1H), 
2.84 (ddt, J = 18.8, 4.4, 1.4 Hz, 1H), 2.80 – 2.71 (m, 1H), 2.47 – 2.32 (m, 4H), 1.95 – 1.73 
(m, 6H); 13C NMR (101 MHz, CDCl3) δ 212.3, 197.4, 146.0, 129.5, 51.5, 45.7, 38.2, 38.1, 
33.7, 27.7, 20.8; IR (Neat Film, NaCl) 3037, 2936, 2865, 1705, 1678, 1446, 1424, 1387, 
1252, 1135, 736 cm-1; HRMS (FAB+) m/z calc’d for C11H15O2 [M+H]+: 179.1072, found 
179.1078. 
 
 
Spectroscopic Data for Spirocyclic Compounds 
 
 
 
(S)-3',4'-dihydro-1'H-spiro[cyclohexane-1,2'-naphthalen]-3-ene-1',5-dione (3b). 
Product 3b was prepared according to the general procedure to give a colorless oil (18 mg, 
77% yield) after preparatory TLC (15% EtOAc/hexanes): [α]D25 –1.5 (c 1.2, CHCl3); 1H 
NMR (400 MHz, CDCl3) δ 8.01 (dd, J = 7.8, 1.4 Hz, 1H), 7.50 (td, J = 7.5, 1.5 Hz, 1H), 
7.40 – 7.30 (m, 1H), 7.26 – 7.20 (m, 1H), 6.91 – 6.77 (m, 1H), 6.10 (dt, J = 10.3, 2.1 Hz, 
1H), 3.09 – 2.89 (m, 3H), 2.82 (d, J = 16.2 Hz, 1H), 2.50 – 2.38 (m, 2H), 2.27 – 2.02 (m, 
2H); 13C NMR (101 MHz, CDCl3) δ 199.2, 197.4, 145.6, 142.7, 133.9, 130.8, 129.5, 128.9, 
128.5, 127.2, 47.7, 44.6, 32.5, 32.3, 25.0; IR (Neat Film, NaCl) 3034, 2926, 2858, 1683, 
1601, 1455, 1388, 1250, 1224, 1157, 946, 750 cm-1; HRMS (FAB+) m/z calc’d for 
C15H15O2 [M+H]+: 227.1072, found 227.1074. 
 
 
 
 
(S)-2-benzoyl-2-azaspiro[5.5]undec-9-ene-1,8-dione (3c). Product 3c was prepared 
according to the general procedure to give a colorless oil (15 mg, 53% yield) after 
preparatory TLC (40% EtOAc/hexanes): [α]D25 +29.7 (c 0.9, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 7.54 – 7.32 (m, 5H), 6.87 (ddd, J = 10.2, 5.0, 3.3 Hz, 1H), 6.06 (dt, J = 10.1, 2.1 
Hz, 1H), 3.91 – 3.74 (m, 2H), 3.09 (dt, J = 18.9, 3.0 Hz, 1H), 2.96 (d, J = 16.1 Hz, 1H), 
2.59 (dd, J = 16.2, 1.3 Hz, 1H), 2.49 (ddt, J = 18.9, 5.0, 1.6 Hz, 1H), 2.09 – 1.95 (m, 4H); 
13C NMR (101 MHz, CDCl3) δ 196.4, 177.0, 175.1, 145.8, 135.8, 131.9, 129.2, 128.5, 
127.6, 47.1, 47.0, 46.4, 34.8, 32.5, 19.3; IR (Neat Film, NaCl) 2949, 1679, 1449, 1388, 
1281, 1151, 919, 729, 694, 665 cm-1; HRMS (FAB+) m/z calc’d for C17H18O3N [M+H]+: 
284.1287, found 284.1277. 
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 13C NMR (101 MHz, CDCl3) of compound 1a. 
 
Infrared spectrum (Thin Film, NaCl) of compound 1a. 
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 13C NMR (101 MHz, CDCl3) of compound 1b. 
 
Infrared spectrum (Thin Film, NaCl) of compound 1b. 
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 13C NMR (101 MHz, CDCl3) of compound 1c. 
 
Infrared spectrum (Thin Film, NaCl) of compound 1c. 
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 13C NMR (101 MHz, CDCl3) of compound 2a. 
 
Infrared spectrum (Thin Film, NaCl) of compound 2a. 
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 13C NMR (101 MHz, CDCl3) of compound 2b. 
 
Infrared spectrum (Thin Film, NaCl) of compound 2b. 
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 13C NMR (101 MHz, CDCl3) of compound 2c. 
 
Infrared spectrum (Thin Film, NaCl) of compound 2c. 
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 13C NMR (101 MHz, CDCl3) of compound 3a. 
 
Infrared spectrum (Thin Film, NaCl) of compound 3a. 
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 13C NMR (101 MHz, CDCl3) of compound 3b. 
 
Infrared spectrum (Thin Film, NaCl) of compound 3b. 
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 13C NMR (101 MHz, CDCl3) of compound 3c. 
 
Infrared spectrum (Thin Film, NaCl) of compound 3c. 
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